2014 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/04/14ResMed Unveils AirCurve 10 Series - Bringing More Therapy Choices to the ResMed Air Solutions Series
Newest Offerings in Air Solutions Connected Care Platform, Advance Patient Care and Streamline Workflows for Providers SAN DIEGO, Dec. 4, 2014 /PRNewswire/ -- ResMed (NYSE:RMD) is launching its new AirCurve™ 10 series, which includes three bilevel devices for specialized support of challenging sleep apnea cases, as well as an adaptive servo-ventilation device for patients with central sleep apnea or Cheyne-Stokes respiration. "We've developed the AirCurve 10 series for patients who ... 
Printer Friendly Version
11/18/14ResMed's New S+ Consumer Sleep Monitor Now Integrates With Apple HealthKit
Sleep Habits can be Self-Monitored From an iPhone With the New S+ by ResMed; Now Available at Apple Retail and Online Stores SAN DIEGO, Nov. 18, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), a leading innovator in sleep, recently launched the all-new S+, the world's first non-contact, personal sleep monitoring device. ResMed today announced S+ availability through Apple retail stores in the United States and from the Apple Online Store (www.apple.com). The free S+ by ResMed App now integrates wi... 
Printer Friendly Version
10/23/14RESMED Inc. Announces Results for the First Quarter of Fiscal Year 2015
First quarter revenue increased by 6% to $380 million First quarter GAAP diluted earnings per share of $0.58 First quarter operating cash flow of $86.5 million Company repurchased 835,000 shares in the first quarter Company successfully launches AirSense 10 platform globally SAN DIEGO, Oct. 23, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its quarter ended September 30, 2014. Revenue for the quarter was $380.4 million, a 6 percent increase compared to... 
Printer Friendly Version
10/21/14ResMed myAir™ Patient Engagement Platform Supports and Coaches Patients to Improve Compliance
SAN DIEGO, Oct. 21, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) today introduced myAir, a new personalized therapy management application for patients with sleep-disordered breathing. myAir equips patients with the information they need to resolve basic therapy issues so they can increase their comfort and stay compliant. By providing well-timed support, education and troubleshooting tools, myAir helps patients feel confident and motivated to start and stay on therapy. Empowering patients to take an... 
Printer Friendly Version
10/21/14ResMed Enhances U-Sleep Patient Management Platform With Action View For Easier Management By Exception
Upgraded Software Automatically Groups Patients for Specific Action Enabling More Efficient Follow-Up and Care SAN DIEGO, Oct. 21, 2014 /PRNewswire/ --ResMed (NYSE:RMD) today announced a significant improvement to U-Sleep, its premium patient management platform, which allows home medical equipment providers (HMEs) to quickly and effectively manage patients with sleep apnea and respiratory conditions. U-Sleep's new Action View feature gives HMEs a fast method of sorting patients into action... 
Printer Friendly Version
10/20/14ResMed Launches ResMed Data Exchange
It's Now Easier and Faster for Health Care Providers to Integrate Patient Sleep and Respiratory Data into Their Software Systems SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- ResMed (NYSE:RMD) today announced the availability of the ResMed Data Exchange program, a comprehensive suite of software and service solutions for home medical equipment (HME) and other health care providers. ResMed Data Exchange offers timely, secure access to critical patient information. It integrates valuable sleep... 
Printer Friendly Version
10/07/14ResMed Launches S+, the World's First Non-Contact System That Helps Consumers Measure, Analyze and Improve Their Sleep
Global Leader in Sleep and Respiratory Medicine Launches New Consumer Device That Monitors Sleep Patterns and the Sleep Environment and Delivers Guidance Combined with Smart Features to Help Achieve a Healthy Sleep SAN DIEGO, Oct. 7, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), a leading innovator in sleep that has been changing lives for more than 25 years, today announced S+ by ResMed, the world's first non-contact sleep system. The S+ by ResMed is a personalized sleep solution that uses pate... 
Printer Friendly Version
10/02/14ResMed To Announce First Quarter 2015 Results
SAN DIEGO, Oct. 2, 2014 /PRNewswire/ -- RESMED INC. (NYSE: RMD) today announced that it will report its first quarter of fiscal year 2015 results on Thursday, October 23, 2014, after the New York Stock Exchange market close. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and future outlook. The earnings call is scheduled to begin at 1:30 p.m. US Pacific Time and the live webcast of the call ... 
Printer Friendly Version
10/01/14ResMed Launches Initiative to Help Women Get Better Sleep
Quality Sleep Needs to Be a Health Priority for Women, Experts Say SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), a pioneer and innovator in helping people sleep and the first company to design complete sleep apnea solutions specifically for women, is launching a new initiative to educate women about the importance of a good night's sleep. The Better Sleep For Women initiative will challenge the myth that feeling tired is just part of living a busy life. It will encourage wo... 
Printer Friendly Version
09/29/14ResMed and Brightree Strengthen Integrated Sleep Compliance Management Capabilities
Seamless workflows between Brightree and ResMed's U-Sleep™ and AirView™ platforms create new efficiencies for providers and better outcomes for patients. SAN DIEGO, Sept. 29, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that it has expanded its relationship with Brightree, the leading provider of home medical equipment (HME) billing and business management software solutions. The two companies have agreed to both enhance the existing integration of ResMed's U-Sleep premium ... 
Printer Friendly Version
09/15/14ResMed and Fairview Health Services Introduce Integration of Sleep and Respiratory Therapy Data into EHR System
ResMed AirView™ patient management system and Fairview Health Services' electronic health record (EHR) system securely exchange patient data to improve patient outcomes and drive operational efficiencies SAN DIEGO, Sept. 15, 2014 /PRNewswire/ -- ResMed today announced that its AirView compliance management platform (previously EasyCare Online) is now securely connected to Fairview Health Services' Epic EHR system, enabling up to date delivery of sleep apnea patient data for use by Fairview'... 
Printer Friendly Version
09/04/14APEX and ResMed Resolve Patent Disputes
SAN DIEGO and TAIPEI, Taiwan, Sept. 4, 2014 /PRNewswire/ -- ResMed Inc. and APEX Medical Corp. have agreed to a confidential settlement resolving their outstanding patent disputes. Under the agreement, APEX has the right to sell and import globally its Wizard masks, as well as its XT and iCH flow generators. APEX agreed to dismiss all validity challenges to ResMed patents, and ResMed agreed to dismiss pending litigation. Additional details of the settlement are confidential.           In acco... 
Printer Friendly Version
09/02/14ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S.
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) has introduced the Astral™ 100 and Astral™ 150 devices in the United States. The Astral platform is ResMed's new generation of portable, lightweight, and user-friendly life support ventilators. ResMed's new Astral life support ventilators offer unparalleled mobility and ease of use for patients suffering from neuromuscular disease, chronic obstructive pulmonary disease (COPD), and other adult and childhood respiratory disorders. T... 
Printer Friendly Version
08/31/14ESC Congress 2014 Highlights: Heart Failure Patients with Sleep-Disordered Breathing More Accurately Diagnosed Through At-Home, Contactless SleepMinderTM Device Than Single Hospital-Based Assessment
Study highlights bedside device could reduce misdiagnosis of sleep-disordered breathing common heart failure co-morbidity, support optimal treatment and reduce need for inpatient care BARCELONA, Spain--(BUSINESS WIRE)--Aug. 31, 2014-- ResMed (NYSE: RMD), a pioneer and global leader in sleep and respiratory medicine, today announced results from a study presented at the ESC Congress 2014 in Barcelona, Spain, looking at the use of the at-home, c... 
Printer Friendly Version
08/31/14ESC Congress 2014 highlights: Treating cardiac patients who have sleep apnoea with positive airway pressure (PAP) therapy shown to reduce mortality up to 38%
Analysis of over 4 million patient records highlights the importance of diagnosis and effective treatment of this prevalent cardiac co-morbidity BARCELONA--(BUSINESS WIRE)--Aug. 31, 2014-- ResMed (NYSE: RMD), a pioneer and global leader in sleep and respiratory medicine, today announced results from a major analysis of the German Statutory Health Insurance (SHI) database presented at a Rapid Fire session at the ESC Congress 2014 in Barcelona, ... 
Printer Friendly Version
08/24/14ResMed Wins Initial Decision in ITC Patent Infringement Action
Judge Finds Nine BMC Products Infringe ResMed Patents Judge Recommends Excluding U.S. Sale of BMC Masks and BMC Humidifier SYDNEY and SAN DIEGO, Aug. 24, 2014 /PRNewswire/ -- An administrative law judge at the International Trade Commission (ITC) ruled Friday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC products named in the action infringes one or more ResMed patents.  As a ... 
Printer Friendly Version
08/18/14ResMed's New AirSense 10 CPAP and APAP Devices Deliver Superior Patient Comfort and Cost-Saving Efficiency for Healthcare Providers
Intelligent AirSense 10 Flow Generators Promote Precise, Personalized Patient Care SAN DIEGO, Aug. 18, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), the industry leader in patient-comfort innovation, today introduced its new AirSense™ 10 positive-airway pressure (PAP) device platform, with breakthrough features that benefit both the patient and the healthcare provider. "Our home medical equipment provider customers are faced with the challenge of balancing superior care with the realiti... 
Printer Friendly Version
08/11/14A New Beginning: ResMed's New Air Solutions Connected Care Platform for Treating Sleep-Disordered Breathing
Platform Maximizes the Power of Data from Diagnosis to Patient Engagement for the Benefit of All Stakeholders in the Care Continuum SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) today announced Air Solutions, a new forward-thinking connected care solution for treating sleep-disordered breathing that can benefit all stakeholders in the care continuum. The ResMed Air Solutions platform has data-driven components that span from diagnosis to treatment, compliance management and pa... 
Printer Friendly Version
08/04/14Long-term Non-invasive Positive Pressure Ventilation Treatment Delivers 76 Percent Reduction in Risk of Death at One Year among Stable COPD Patients
New Study Published in The Lancet Respiratory Medicine is First to Provide Strong Evidence Supporting Long-term NPPV in the Treatment of COPD SAN DIEGO, Aug. 4, 2014 /PRNewswire/ -- Long-term non-invasive positive pressure ventilation (NPPV) – also known as non-invasive ventilation -- significantly improved long-term survival, exercise capacity, and health-related quality of life when added to current guidelines for the treatment of patients with advanced-stage chronic obstructive pulmonary... 
Printer Friendly Version
07/31/14RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014
Fourth quarter revenue of $415 million Fourth quarter GAAP earnings per share of $0.61 and non-GAAP earnings per share of $0.64 Operating cash flow of $115.6 million in the fourth quarter Quarterly dividend increased by 12% to $0.28 per share SAN DIEGO, July 31, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its fourth quarter and for the fiscal year ended June 30, 2014.  Revenue for the quarter was $415.2 million, flat compared to the quarter ended June 3... 
Printer Friendly Version
07/28/14ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
Trial court awards permanent injunction, damages and costs against APEX MUNICH, July 28, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks.  The judgment wa... 
Printer Friendly Version
07/21/14ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
Additional Redesigned APEX CPAP Humidifier Deemed 'Inferior' by APEX Expert SAN DIEGO, July 21, 2014 /PRNewswire/ -- An International Trade Commission (ITC) ruling issued Friday held that, despite a redesign of its iCH CPAP device, Taiwanese device manufacturer APEX continues to infringe ResMed patents in its humidification. ResMed (NYSE: RMD) is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing. "Our research... 
Printer Friendly Version
07/10/14ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results
SAN DIEGO, July 10, 2014 /PRNewswire/ -- RESMED INC. (NYSE: RMD) today announced that it will report its fourth quarter and fiscal year ended June 30, 2014 results on Thursday, July 31, 2014, after the New York Stock Exchange market close. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and future outlook. The earnings call is scheduled to begin at 1:30 p.m. US Pacific Time and the live webca... 
Printer Friendly Version
06/30/14The American Sleep Apnea Association Receives Unprecedented ResMed Donation That Will Save Lives
WASHINGTON, D.C. – June 30, 2014 -- The American Sleep Apnea Association (ASAA) today announced that ResMed (NYSE: RMD), a leading manufacturer of devices for the treatment of sleep-disordered breathing, has donated more than 10,000 continuous positive airway pressure (CPAP) devices to the ASAA CPAP assistance program (CAP). CAP is just one of the support programs offered to patients by the ASAA. It provides a package containing a CPAPdevice, tubing, filters and mask to patients who otherw... 
Printer Friendly Version
06/04/14ITC Judge Rules APEX Infringes ResMed Patents
Products banned from sale in United States SAN DIEGO, June 4, 2014 /PRNewswire/ -- An International Trade Commission (ITC) judge ruled today that Taiwanese device manufacturer APEX infringes a ResMed patent protecting an integrated humidifier used in flow generator devices. According to the ruling, the APEX XT and iCH flow generators with infringing humidifiers cannot be imported or sold in the United States. ResMed (NYSE: RMD), the innovation leader and pioneer in designing and manufacturi... 
Printer Friendly Version
05/21/14Redefining Sleep Apnea Treatment for Women: New Algorithm Significantly Improves Treatment of Flow Limitation
Enables lower pressures over the course of the night than standard APAP SAN DIEGO, May 21, 2014 /PRNewswire/ -- A new study presented today at the American Thoracic Society 2014 International Conference (Abstract #714) indicates that a new algorithm developed specifically for how female sleep apnea sufferers breathe and who use auto-adjusting positive airway pressure (APAP) therapy can improve flow limitation and enable lower pressures for therapy, leading to a more comfortable therapy expe... 
Printer Friendly Version
05/12/14ResMed Launches New Platform Of Portable And Lightweight Life Support Ventilators
Astral 100 and Astral 150 Redefine Mobile Life Support Ventilation SAN DIEGO, May 12, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) today introduced a new platform of portable, lightweight, and user-friendly life support ventilators in select European and Asia-Pacific markets with the launch of the Astral™ 100 and Astral™ 150. Already a leading player with its Elisée™ and VS III™ devices, ResMed's new generation of Astral life support ventilators offer unparalleled mobility and ease of use for pa... 
Printer Friendly Version
04/23/14Resmed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2014
SAN DIEGO, April 23, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended March 31, 2014.  Revenue for the quarter was $397.8 million, a 4 percent increase (a 3 percent increase on a constant currency basis) over the quarter ended March 31, 2013.  Net income was $90.0 million, an increase of 6 percent compared to the quarter ended March 31, 2013.  Diluted earnings per share for the quarter were $0.63, an increase of 9 pe... 
Printer Friendly Version
04/21/14ResMed Adds To AirFit Line Of Masks With Compact Full Face And Nasal Options
AirFit F10 and AirFit N10 Masks Provide Comfort, Stability, and Ease of Use SAN DIEGO, April 21, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) expands its ultra-light, comfortable, and award-winning AirFit™ line of masks today with new nasal and full face options. The AirFit F10 compact full face mask and AirFit N10 compact nasal mask continue the company's 25-year history of innovating comfortable and effective solutions for treating sleep-disordered breathing. "These new masks embody the A... 
Printer Friendly Version
04/14/14ResMed Innovation Excellence Earns Two Red Dot Design Awards For 2014
Dual Win Highlights Innovation in Patient-Centric Design SAN DIEGO, April 14, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other respiratory conditions, has won two Red Dot Product Design Awards for 2014 — one for its AirFit™ P10 nasal pillows mask and one for its soon-to-be-launched Astral™ 150 life support ventilator. A repeat winner, having been recognized in 2010 for its S9™ Se... 
Printer Friendly Version
03/25/14ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2014 Results
SAN DIEGO, March 25, 2014 /PRNewswire/ -- RESMED INC. (NYSE: RMD) announced today that on Wednesday, April 23, 2014, it will release its results for the third quarter and nine months of fiscal year 2014, ended March 31, 2014. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a conference call and webcast to review its results, market trends, and future outlook. The conference call is scheduled to begin at 1:30 p.m. US Pacific ... 
Printer Friendly Version
03/14/14Landmark Year in Sleep: Leader in Sleep and Respiratory Medicine Highlights Top Five Sleep Apnea Research Findings
SAN DIEGO, March 14, 2014 /PRNewswire/ -- To coincide with today's World Sleep Day, ResMed (NYSE: RMD), an innovator and pioneer in developing solutions for treating sleep-disordered breathing and other respiratory conditions, highlights its pick for the top five research discoveries about sleep apnea from the past year. Together, they paint an alarming picture: sleep apnea is on the rise and linked to sudden cardiac death, slower recovery from heart attacks, cancer, and high blood pressure. ... 
Printer Friendly Version
03/10/14First Time in its 25-year History, ResMed Unveils a New Brand, Reflecting Commitment to Changing Lives
SAN DIEGO, March 10, 2014 /PRNewswire/ -- "Changing lives with every breath." That's the new tagline accompanying a refreshed ResMed (NYSE: RMD) brand that aligns ResMed's appearance in the marketplace with its global focus on innovation that benefits patients' lives. ResMed's new logo includes an updated wordmark combined with a visually appealing "pulse" curve that shifts in color from bright blue to rich red, symbolizing the transition that deoxygenated blood makes to oxygenated blood with e... 
Printer Friendly Version
01/23/14ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended Dec. 31, 2013
SAN DIEGO, Jan. 23, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended Dec. 31, 2013.  Revenue for the quarter ended Dec. 31, 2013 was $384.3 million, a 2 percent increase (a 1 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012.  For the quarter ended Dec. 31, 2013, net income was $86.6 million, an increase of 11 percent compared to the quarter ended Dec. 31, 2012.  Diluted earnings per share for the quart... 
Printer Friendly Version
01/13/14ResMed's New Nasal Pillows System is Our Quietest Yet; Ultra-light AirFit P10 Packs Powerful Performance in Just over 1.5 Ounces
SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- ResMed (NYSE: RMD) continues its 25-year history of innovating powerful and comfortable solutions for treating sleep-disordered breathing with today's introduction of the ultra-light, ultra-quiet ResMed AirFit™ P10 nasal pillows system. (Photo:  http://photos.prnewswire.com/prnh/20140113/LA44444-a) (Photo:  http://photos.prnewswire.com/prnh/20140113/LA44444-b) (Logo:  http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO) The AirFit P10 weigh... 
Printer Friendly Version